OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
NEWARK, Calif., March 30, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies for specialty and orphan diseases with high unmet medical need, today announced that management will provide a corporate overview at the H.C. Wainwright & Co. 1st Annual NASH Investor Conference, being held April 3, 2017 at the St. Regis Hotel in New York City, and the BioCentury Future Leaders in the Biotech Industry Conference, being held April 7 at the Millennium Broadway Hotel & Conference Center in New York City.
| 1st Annual NASH Investor Conference | |
| Date: | Monday, April 3 |
| Time: | 11:40am Eastern Time |
| Location: | St. Regis Hotel, New York City |
| Webcast: | http://ir.cymabay.com/events |
| BioCentury Future Leaders in the Biotech Industry Conference | |
| Date: | Friday, April 7 |
| Time: | 1:30pm Eastern Time |
| Location: | Millennium Broadway Hotel & Conference Center, New York City, NY |
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Seladelpar is a potent, selective, orally active PPARδ agonist. A Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed Phase 2 studies for seladelpar in subjects with primary biliary cholangitis and homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Arhalofenate, CymaBay’s other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
